CIA
VRTX icon

Concurrent Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Concurrent Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.04M Buy
10,145
+661
+7% +$293K 0.04% 432
2026
Q1 		$4.23M Sell
9,484
-250
-3% -$117K 0.05% 393
2025
Q4 		$4.41M Buy
9,734
+6,895
+243% +$2.97M 0.05% 361
2025
Q3 		$1.11M Sell
2,839
-281
-9% -$117K 0.02% 623
2025
Q2 		$1.39M Sell
3,120
-93
-3% -$42.9K 0.03% 517
2025
Q1 		$1.56M Buy
3,213
+1,141
+55% +$532K 0.04% 421
2024
Q4 		$834K Hold
2,072
– – 0.02% 532
2024
Q3 		$964K Buy
2,072
+541
+35% +$260K 0.03% 471
2024
Q2 		$718K Buy
1,531
+244
+19% +$106K 0.02% 507
2024
Q1 		$538K Buy
1,287
+621
+93% +$263K 0.02% 531
2023
Q4 		$271K Buy
+666
New +$246K 0.01% 680

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Concurrent Investment Advisors's VRTX Position: Q2 2026 in Review

Concurrent Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 7% in Q2 2026, buying an estimated $293K and bringing the position to 10,145 shares worth $5.04M. The position accounts for 0.04% of the portfolio, ranked #432.

Concurrent Investment Advisors first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Concurrent Investment Advisors held 10,145 shares of Vertex Pharmaceuticals worth $5.04M as of Q2 2026.
  • Concurrent Investment Advisors bought 661 Vertex Pharmaceuticals shares in Q2 2026, an estimated $293K.
  • Vertex Pharmaceuticals made up 0.04% of Concurrent Investment Advisors's portfolio in Q2 2026, its #432 holding.
  • Concurrent Investment Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.